ReGen Biologics, Inc. designs, develops, manufactures, and markets medical devices for the repair and generation of soft tissue in humans, primarily for orthopedic applications. The company's proprietary collagen matrix technology includes applications in orthopedics, general surgery, spine, cardiovascular, and drug delivery. Its products include Menaflex collagen meniscus implant device, for use in surgical procedures for the reinforcement and repair of soft tissue injuries of the medial meniscus; and SharpShooter Tissue Repair System, an instrument that allows surgeons to place needles in hard-to-reach locations of the meniscus. The company sells its products in the United States, the European Union, the Republic of South Africa, Canada, Australia, Chile, and Japan. ReGen Biologics, Inc. was founded in 1987 and is headquartered in Hackensack, New Jersey.
There are fifteen full-time employees with the company.
OTC-Killers-Clubhas spot 182 stock killers from 4900-bagger to 2.33-bagger since 03/05/2011
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.